biostudies-literatureMbala-Kingebeni PFogarty International Center NIH/CRDFBill & Melinda Gates FoundationWorld Health OrganizationFIC NIH HHSNIAID NIH HHSNational Cancer InstituteNCI NIH HHSNational Institutes of HealthBill and Melinda Gates FoundationNIH HHSNIGMS NIH HHSNational Science Foundation1240-1247https://www.ebi.ac.uk/biostudies/studies/S-EPMC7888312biostudies-literatureUnknown384(13)During the 2018-2020 Ebola virus disease (EVD) outbreak in North Kivu province in the Democratic Republic of Congo, EVD was diagnosed in a patient who had received the recombinant vesicular stomatitis virus-based vaccine expressing a ZEBOV glycoprotein (rVSV-ZEBOV) (Merck). His treatment included an Ebola virus (EBOV)-specific monoclonal antibody (mAb114), and he recovered within 14 days. However, 6 months later, he presented again with severe EVD-like illness and EBOV viremia, and he died. We initiated epidemiologic and genomic investigations that showed that the patient had had a relapse of acute EVD that led to a transmission chain resulting in 91 cases across six health zones over 4 months. (Funded by the Bill and Melinda Gates Foundation and others.).The New England journal of medicineEbola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease.PMC78883123U19AI135995U01AI151812UL1TR002550U19 AI135995INV-003565DGE-1256082001U01 AI151812U19AI135995INV-004176GM119774-01Contract# 75N91019D00024 Task Order No. 75N91019F0FOGX-19-90402-1R35 GM119774Sana-Paka EMutafali-Ruffin MSuchard MAMbala-Kingebeni PMambu FBula Bula JHensley LNkuba-Ndaye AWiley MRFaye OFaye MPloquin AMulangu SMukadi DGangavarapu KBedford TAziza ADiallo BSall ASullivan NJBelizaire MRDPratt CKinganda-Lusamaki EPauthner MGCrozier IRambaut AEpaso VMuyembe Tamfum JJYam ADiagne MMAkonga MKeita MRimoin AWFall ISN'kasar YTTBile FEdidi FWhite BAhuka-Mundeke SBlack AHadfield JSalfati EKazadi DNsunda BTshiani OAndersen KGBisento NMatondo MMisasi JTorkamani AfalseEbola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease.During the 2018-2020 Ebola virus disease (EVD) outbreak in North Kivu province in the Democratic Republic of Congo, EVD was diagnosed in a patient who had received the recombinant vesicular stomatitis virus-based vaccine expressing a ZEBOV glycoprotein (rVSV-ZEBOV) (Merck). His treatment included an Ebola virus (EBOV)-specific monoclonal antibody (mAb114), and he recovered within 14 days. However, 6 months later, he presented again with severe EVD-like illness and EBOV viremia, and he died. We initiated epidemiologic and genomic investigations that showed that the patient had had a relapse of acute EVD that led to a transmission chain resulting in 91 cases across six health zones over 4 months. (Funded by the Bill and Melinda Gates Foundation and others.).2021-01-01T00:00:00Z2021 Apr2024-11-12T15:01:21.995Z2022-02-09T11:05:50.828ZS-EPMC78883123378901210.1056/NEJMoa2024670